JPRN-jRCT2080224813已完成2 期
KD2-305 phase II/III study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 11
研究概览
简要总结
MC710 prophylaxis is considered to be decrease the bleeding rate in hemophilia B patients with inhibitors without safety concerns.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Congenital haemophilia A or B patients with inhibitors to factor VIII or factor IX.
- •(2)Patients who or whose legally acceptable representatives have provided written informed consent.
排除标准
- •(1) Pediatric patients (aged 18 years or younger) for Part 1
- •(2) Patients undergoing immune tolerance induction (ITI) treatment
- •(3) Patients with diseases that develop abnormality in the coagulation/fibrinolytic system other than the target disease of the study or suspected of such
- •(4) Patients with hypercoagulability or such possibilities
- •(5) Patients with a history of disseminated intravascular coagulation (DIC) or thromboembolism
- •(6) Patients with a history of shock or hypersensitivity to protein preparations such as blood derivatives
- •(7) Patients who have undergone surgical procedure and have not fully recovered when participating in the study or patients who are scheduled to undergo surgery during the study
- •(8) Patients with acquired immunodeficiency syndrome (AIDS) defining illness
- •(9) Patients with severe liver disorder or renal disorder
- •(10) Patients with current serious medical conditions such as malignant tumor or leukaemia who will or are highly likely to undergo chemotherapy or radiotherapy during the study
- •(11) Patients with hemolytic or blood loss anaemia
- •(12) Patients who have participated in any other clinical study and received any investigational product within 1 month prior to the informed consent for the study or patients who are participating, or who are scheduled to participate during the study, in any other clinical study at the time of informed consent for the study
- •(13) Patients who have received HEMLIBRA (R) Subcutaneous Injection within 4 months prior to the informed consent for the study
- •(14) Patients who are considered ineligible for the study by the investigator or subinvestigator for any other reason
研究者
相似试验
进行中（未招募）
3 期
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsHemophilia A With InhibitorHemophilia B With InhibitorNCT06312475Suzhou Alphamab Co., Ltd.53
进行中（未招募）
3 期
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsHemophilia A Without InhibitorHemophilia B Without InhibitorNCT06569108Suzhou Alphamab Co., Ltd.125
Unknown
不适用
Clinical and Health-related Outcome of rFVIIIFc ProphylaxisHemophilia ANCT04583930Prof. Dr. Dr. Thomas Hilberg48
尚未招募
不适用
Stop study.haemophilia, prophylaxis, adherence, bleeds, arthropathy.hemofilie, profylaxe, therapietrouw, bloedingen, arthropathie.NL-OMON25201niversity Medical Center Utrecht (UMC Utrecht)90
终止
1 期
Hemophilia B Gene Therapy With AAV8 VectorHemophilia BNCT01620801Spark Therapeutics, Inc.4